Outsourcing Your Way Into Trouble: Pfizer Issues Recall After Indian Aurobindo Mislabels Bottles
This article was originally published in PharmAsia News
Executive Summary
India-based Aurobindo Pharma Ltd. may find itself in a little hot water with business partner Pfizer Inc. after forcing a recall because bottles of an anti-depressant drug may have been mislabeled as a benign prostatic hyperplasia treatment
You may also be interested in...
FDA Warning Letters Hit Inadequate Investigations and QC Failings
In recent warning letters, FDA continued to hammer manufacturers for inadequate investigation of out-of-specification results and lax oversight of manufacturing operations by quality control units.
FDA Warning Letters Hit Inadequate Investigations and QC Failings
In recent warning letters, FDA continued to hammer manufacturers for inadequate investigation of out-of-specification results and lax oversight of manufacturing operations by quality control units.
Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
Pfizer Inc. and Shanghai-based Zhejiang Hisun Pharmaceuticals announced June 2 a memorandum of understanding to potentially establish a joint venture to develop, manufacture and sell branded generics in China and other markets